Table 3.
Comparison between RV3-BB and RIX4414 neonatal oral live-attenuated human rotavirus (HRV) candidates.
| Dose | RV3-BB | RIX4414 ≈ Rotarix® | ||||||
|---|---|---|---|---|---|---|---|---|
| IgA Response (Neonates) | Neonatal Stool Shedding | IgA Response (Infants) | Infant Stool Shedding | Vaccine Concentration (FFU/mL) | IgA Response (Infants) | Infant Stool Shedding | ||
| 1D | 2Ds | |||||||
| 1 | 23% | 4% | Placebo | - | 104.7 (with antacid) | 100% | 42% | 8% |
| 2 | 54% | 42% | 44% | 41% | 104.1 (with buffer) | 74% | 38% | 13% |
| 3 | 94% | 70% | 86% | 62% | 104.7 (with buffer) | 93% | 60% | 8% |
| 4 | Placebo | - | 99% | 76% | 105.8 (with buffer) | 96% | 55% | 0 |
Shedding of RV3-BB was 3 and 7 days after vaccine administration while shedding of RIX4414 was 7 and 9 days after vaccine administration.